key: cord-0684968-wtixenit authors: Lake, Douglas F.; Roeder, Alexa J.; Kaleta, Erin; Jasbi, Paniz; Pfeffer, Kirsten; Periasamy, Calvin Koelbela Sivakumar; Kuzmina, Natalia; Bukreyev, Alexander; Grys, Thomas E.; Wu, Liang; Mills, John R; McAulay, Kathrine; Gonzalez-Moa, Maria; Seit-Nebi, Alim; Svarovsky, Sergei title: Development of a Rapid Point-Of-Care Test that Measures Neutralizing Antibodies to SARS-CoV-2 date: 2021-11-04 journal: J Clin Virol DOI: 10.1016/j.jcv.2021.105024 sha: 5d10123789750022276f591e395956451f7ece02 doc_id: 684968 cord_uid: wtixenit BACKGROUND: After receiving a COVID-19 vaccine, most recipients want to know if they are protected from infection and for how long. Since neutralizing antibodies are a correlate of protection, we developed a lateral flow assay (LFA) that measures levels of neutralizing antibodies from a drop of blood. The LFA is based on the principle that neutralizing antibodies block binding of the receptor-binding domain (RBD) to angiotensin-converting enzyme 2 (ACE2). METHODS: The ability of the LFA was assessed to correctly measure neutralization of sera, plasma or whole blood from patients with COVID-19 using SARS-CoV-2 microneutralization assays. We also determined if the LFA distinguished patients with seasonal respiratory viruses from patients with COVID-19. To demonstrate the usefulness of the LFA, we tested previously infected and non-infected COVID-19 vaccine recipients at baseline and after first and second vaccine doses. RESULTS: The LFA compared favorably with SARS-CoV-2 microneutralization assays with an area under the ROC curve of 98%. Sera obtained from patients with seasonal coronaviruses did not show neutralizing activity in the LFA. After a single mRNA vaccine dose, 87% of previously infected individuals demonstrated high levels of neutralizing antibodies. However, if individuals were not previously infected only 24% demonstrated high levels of neutralizing antibodies after one vaccine dose. A second dose boosted neutralizing antibody levels just 8% higher in previously infected individuals, but over 63% higher in non-infected individuals. CONCLUSIONS: A rapid, semi-quantitative, highly portable and inexpensive neutralizing antibody test might be useful for monitoring rise and fall in vaccine-induced neutralizing antibodies to COVID-19. Conclusions: A rapid, semi-quantitative, highly portable and inexpensive neutralizing antibody test might be useful for monitoring rise and fall in vaccine-induced neutralizing antibodies to COVID-19. Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) causes COVID-19 and originated in Wuhan, China in December 2019 [1] [2] [3] . Vaccines continue to be tested [4, 5] with the goal of preventing COVID-19 via induction of neutralizing antibodies (NAbs) and anti-viral T cells. Vaccine trials show that RNA vaccines elicit protective immunity, but durability of natural and vaccine-induced immunity is not fully known [5] . Several groups reported that up to one-third of serum samples from individuals who recovered from COVID-19 do not neutralize SARS-CoV-2 [6] [7] [8] . Whether previously infected or vaccinated, it is informative for individuals to learn if they generated high levels of NAbs so that they can resume normal activities without fear of re-infection and transmitting the virus [9] [10] [11] . Viral neutralization assays measure antibodies that block infection of host cells. The gold standard of neutralization for SARS-CoV-2 measures reduction of viral plaques or foci in microneutralization assays. These assays are slow, laborious, require highly trained personnel and a BSL3 facility. Another challenge is that neutralization assays require careful titration of virus and depend on host cells for infection, both of which add variability to the assay. These limitations prevent use of SARS-CoV-2 neutralization assays for clinical applications. SARS-CoV-2 uses receptor binding domain (RBD) on spike protein to bind angiotensin converting enzyme 2 (ACE2) on host cells; RBD appears to be the principal neutralizing domain [12, 13] . Using this knowledge, we developed a lateral flow assay (LFA) that measures levels of NAbs which block RBD from binding to ACE2. Other groups have developed RBD-ACE2-based competition ELISAs [18, 19] but none have developed a rapid, highly portable, semi-quantitative test that can easily be incorporated into clinical settings or research studies where traditional laboratory or neutralization tests are not practical. Serum and finger-stick blood samples were collected for this study under an A microneutralization assay was performed using a recombinant SARS-CoV-2 expressing mNeonGreen (SARS-CoV-2ng) as previously described [16] . Inhibitory The Lateral Flow NAb assay was developed to measure levels of antibodies that compete with ACE2 for binding to RBD. The LFA single port cassette (Empowered Diagnostics) contains a test strip composed of a sample pad, blood filter, conjugate pad, nitrocellulose membrane striped with test and control lines, and an absorbent pad (Axim Biotechnologies Inc). The LFA also contains a control mouse antibody conjugated to red gold nanospheres and corresponding anti-mouse IgG striped at the control line. LFAs were run at room temperature on a flat surface for 10 minutes prior to reading results. To perform the test, 6.7µl of serum or 10ul whole blood were added to the sample port followed by 60µl of chase buffer. After 10 minutes, densities of both test and control lines were recorded in an iDetekt RDS-2500 density reader. The test leverages the interaction between RBD-conjugated green-gold nanoshells (Nanocomposix) that bind ACE2 at the test line when RBD-neutralizing antibodies (RBD-NAbs) are absent or low. Test line density is inversely proportional to RBD-NAbs present within the sample. As a semi-quantitative test, the results of the LFA can be interpreted using a scorecard or a densitometer. A red line across from the -C‖ indicates that the test ran properly. An absent or faint test line indicates high levels of RBD-NAbs, whereas a dark test line suggests low or lack of RBD-NAbs. Precision testing was performed using sera from one highly, and one nonneutralizing donor in replicates of 10 . Density values were recorded as above and %CVs calculated using the formula: (Standard Deviation/Mean) * 100%. Pearson's correlation (r) was conducted to assess the strength and significance of associations between the LFA, the Ortho Vitros test and IC 50 values. Regression analysis using IC 50 values evaluated consistency [14] while Bland-Altman plots assessed agreement and bias [17, 18] . Correlation analysis was conducted using IBM SPSS. For two-group analysis, IC 50 values corresponding to >240 were categorized as titer of ≥1:320 (neutralizing), whereas IC 50 values ≤240 were categorized as ≤1:160 (low/non-neutralizing). Receiver operating characteristic (ROC) analysis was performed to assess accuracy, sensitivity, and specificity of the LFA and Ortho Vitros tests in assessing neutralization; optimal cutoffs for each method were established to maximize area under curve (AUC) [19, 20] . ROC analysis was conducted using R language in the RStudio environment (version 3.6.2; RStudio PBC). All analyses were conducted using raw values; data were not normalized, transformed, or scaled. As shown at the bottom in Figure 1A , serum containing high levels of NAbs results in a weak or ghost test line because NAbs bind RBD on green-gold beads, preventing RBD from binding to the ACE2 receptor at the test line. Serum with low levels of NAbs results in a strong test line because little to no antibodies prevent RBD on beads from binding to ACE2. Figure 1B To support the application of the LFA to measure NAb levels to SARS-CoV-2, we tested 38 serum samples that were assigned IC 50 values in a SARS-CoV-2 microneutralization assay [16] . The experiment was performed in a blinded manner such that personnel running either the LFA or the microneutralization assay did not know the results of the comparator test. When line densities from the LFA were plotted against IC 50 values determined in the microneutralization assay, serum samples with strong neutralization activity demonstrated low line densities; this indicates that NAbs inhibited RBD from binding to ACE2 (Figure 2) . Figure S1) . To evaluate bias, mean differences and 95% confidence intervals (CIs) were calculated and plotted alongside limits of agreement (Figure 4) . Both LFA and Ortho Vitros test values showed strong agreement with titer, although the Ortho Vitros test showed a tendency to underestimate neutralizing capacity while the LFA method showed no bias. ROC analysis was performed to assess the ability of the LFA and the Ortho Vitros test to classify low/non-neutralizing (Neg, <1:160), and highly neutralizing groups (≥1:320) ( Figure 5) . As shown in Figure 5B and 5D, the LFA misclassified one non- Precision studies were performed on replicate samples (n=10) and showed a CV of ~9% from a serum sample in the high neutralizing range and ~6% CV in a serum sample from the low neutralizing range (Supplemental Table 1 ). Precision studies were performed on replicate samples (n=10) and showed a CV of ~9% from a serum sample in the high neutralizing range and ~6% CV in a serum sample from the low neutralizing range (Supplemental Table 1 ). Since NAb levels may be considered correlates of protection, we tested sera from RNA vaccine recipients (mRNA-1273 and BNT162b2) in -previously infected‖ and -not previously infected‖ individuals using finger-stick blood in the rapid LFA (Figure 6 ). We developed a rapid test that measures levels of NAbs in serum and whole blood. As shown in Figure 2 , the LFA correlates well with serologic titers determined using a SARS-CoV-2 microneutralization assay, especially when serum sample IC 50 values are >250. Advantages of the LFA test are that it can be inexpensively and rapidly deployed to determine levels of NAbs in vaccine recipients. Moreover, the test can be used longitudinally to evaluate duration of protective immunity in naturally infected and vaccinated individuals-many more than could ever be evaluated using BSL2 or BSL3-based neutralization assays. The LFA and Ortho Vitros test showed a significant correlation with each other (r = -0.572, p < 0.001), displaying good linear relation (r = -0.720, p < 0.001) [21] . The LFA accounts for 52% of observed IC 50 variance (R 2 = 0.5187), while the Ortho Vitros test accounts for 27% (R 2 = 0.2725). Although absolute quantitation demands an excellent coefficient of determination (R 2 ≥ 0.99) [22] , variables with R 2 ≥ 0.5 are highly predictive in univariate regression models while measures with R 2 < 0.5 are recommended for use in multivariate models with complementary measures to increase predictive accuracy [23, 24] . Bland-Altman analysis (Figure 4) After a second vaccine dose, the LFA indicated high levels of NAbs in 87% of recipients, identical to levels observed in previously infected individuals after the first vaccine dose. These findings might suggest that a booster (3 rd vaccine dose) in non-infected individuals could induce the highest levels of NAbs in the most people. Limitations of the LFA are that it uses only the RBD portion of spike protein. Although the vast majority of reports indicate that the principle neutralizing domain is the RBD portion of spike protein, mAbs have been reported that neutralize SARS-CoV-2 by binding to the N-terminal domain of spike protein [31, 32] . Also, since the spike protein assumes multiple conformations during viral binding and entry [33] , neutralizing epitopes exist on the quaternary structure of spike [32] . Although RBDs on the nanoparticles may associate, it is not known if they assume a native conformation. Other limitations are the binary nature of this data analysis (high and low neutralizing) of a continuous assay. NAb levels should be evaluated longitudinally to assess rise and fall in NAb levels; this rapid test is well-suited for that role. Another limitation is that the LFA does not differentiate high affinity anti-RBD NAbs from an abundance of lower affinity anti-RBD NAbs. This test may prove useful in monitoring COVID-19 vaccine recipients as a First known person-to-person transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the USA Clinical features of patients infected with 2019 novel coronavirus in Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV-2) Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals Immunogenic profile of SARS-CoV-2 spike in individuals recovered from COVID-19, Infectious Diseases Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications Discharged COVID-19 Patients Testing Positive Again for SARS-CoV-2 RNA: A Minireview of Published Studies from China Clinical characteristics of severe acute respiratory syndrome coronavirus 2 reactivation Recurrence of positive SARS-CoV-2 in patients recovered from COVID-19 Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2 The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction Targeting ACE2-RBD interaction as a platform for COVID19 therapeutics: Development and drug repurposing screen of an AlphaLISA proximity assay An Infectious cDNA Clone of SARS-CoV-2 Understanding Bland Altman analysis Bland-Altman analysis: A paradigm to understand correlation and agreement Receiver operating characteristic (ROC) curves: review of methods with applications in diagnostic medicine Ordered multiple-class ROC analysis with continuous measurements Correlation Coefficients: Appropriate Use and Interpretation Quantifying explained variance in multilevel models: An integrative framework for defining R-squared measures A framework of R-squared measures for single-level and multilevel regression mixture models New Recommendations on the Use of R-Squared Differences in Multilevel Model Comparisons An mRNA Vaccine against SARS-CoV-2 -Preliminary Report Mini Review Immunological Consequences of Immunization With COVID-19 mRNA Vaccines: Preliminary Results COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19 Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2 A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2 Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike Distinct conformational states of SARS-CoV-2 spike protein ☐ The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.